Perioperative Nivolumab in Resectable Lung Cancer
1. The 18-month event-free survival in the perioperative nivolumab group was 70.2% vs 50.0% in the chemotherapy group with HR ...
Tag: early stage lung cancer
Lobar vs Sublobar Resection for Peripheral Stage IA NSCLC
1. The 5-year disease-free survival, overall survival, and recurrence rates were similar in both lobar vs sublobar resections for patients ...
Adjuvant erlotinib increased overall survival when compared to chemotherapy in stage IIIA EGFR-mutant non-small cell lung cancer
1. Erlotinib showed an overall survival benefit and improved 5-year survival rates when compared to chemotherapy. 2. Disease-free survival was ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
